Myocardial fibrosis refers to a variety of quantitative and qualitative changes in the interstitial myocardial collagen network that occur in response to cardiac ischaemic insults, systemic diseases, drugs, or any other harmful stimulus affecting the circulatory system or the heart itself. Myocardial fibrosis alters the architecture of the myocardium, facilitating the development of cardiac dysfunction, also inducing arrhythmias, influencing the clinical course and outcome of heart failure patients. Focusing on myocardial fibrosis may potentially improve patient care through the targeted diagnosis and treatment of emerging fibrotic pathways. The European Commission funded the FIBROTARGETS consortium as a multinational academic and industrial consortium with the primary aim of performing a systematic and collaborative search of targets of myocardial fibrosis, and then translating these mechanisms into individualized diagnostic tools and specific therapeutic pharmacological options for heart failure. This review focuses on those methodological and technological aspects considered and developed by the consortium to facilitate the transfer of the new mechanistic knowledge on myocardial fibrosis into potential biomedical applications.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Eur J Heart Fail. 2017 Feb;19(2):177-191. doi: 10.1002/ejhf.696
Metabolic syndrome is characterized by dysregulated glucose metabolism and is
We are pleased to announce that Innoprot has been recognised
Acetyl-l-carnitine (ALC) is synthesized in the brain, liver, and kidneys
Neural stem cell (NSC) proliferation and differentiation in the mammalian
Allergic conjunctivitis (AC) is the most common form of allergic
The hepatic content of amyloid beta (Aβ) decreases drastically in